Singapore markets close in 6 hours 23 minutes

VRNA May 2024 12.500 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.15000.0000 (0.00%)
As of 10:31AM EDT. Market open.
Full screen
Previous close0.1500
Open0.1500
Bid0.0000
Ask0.4500
Strike12.50
Expiry date2024-05-17
Day's range0.1500 - 0.1500
Contract rangeN/A
Volume11
Open interest28
  • GlobeNewswire

    Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

    PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2024, and prov

  • GlobeNewswire

    Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

    Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (“VPI” and together with Verona Pharma, the “Company”), have entered into strategic financing agreements providing access to up to $650 million from funds managed by Oaktree C

  • GlobeNewswire

    Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

    PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces eight posters, including two mini oral symposia, on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chron